Roth MKM将CervoMed的价格目标翻倍至15美元, 突显出神经紊乱治疗的潜力。 Roth MKM doubles CervoMed's price target to $15.00, highlighting potential in neurologic disorder treatments.

Roth MKM将其生物技术公司CervoMed(NASDAQ:CRVO)的价格目标提高至15美元, Roth MKM raised its price target for biotech company CervoMed (NASDAQ: CRVO) to $15.00, up from $7.00, with a "buy" rating. 据MarketBeat.com报道,平均"中等购买"评级和共识目标为33.14美元. MarketBeat.com reports an average "Moderate Buy" rating and consensus target of $33.14. CervoMed的重点是治疗与年龄有关的神经紊乱,其主要药物是neflamapimod,针对的是诸如Lewy身体痴呆症和阿尔茨海默氏病等疾病。 CervoMed focuses on treating age-related neurologic disorders, with its lead drug, neflamapimod, targeting conditions like dementia with Lewy bodies and Alzheimer's. 星期二,股票交易额降至2.03美元,共有177 420股交易。 On Tuesday, the stock traded down to $2.03, with 177,420 shares traded.